Skip to content
CEpartner4U
  • Welcome
  • About us
    • Team
    • Jobs
  • Services
    • AR/EC Rep
    • Regulatory affairs
    • Quality system
    • CE/QMS Entry Packages©
    • Clinical evaluation
    • Training
  • UKCApartner4U
  • Information
    • F.A.Q. AR/EC Rep
    • Links
  • Library
  • News
  • Network
  • Contact

About:m.vandervoort

Posts by m.vandervoort :

  • Application of MDR Article 97, 30 June 2023 in Uncategorized
  • Manufacturer’s Declaration in relation to Regulation (EU) 2023/607, 23 June 2023 in Uncategorized
  • MDCG revised guidance 2020-3, 13 May 2023 in Uncategorized
  • Commission guidance on the content and structure of the summary of the clinical investigation report, 8 May 2023 in Uncategorized
  • MDCG 2023-1 Guidance on the health institution exemption under Article 5(5) of the MDR and IVDR, 23 January 2023 in Uncategorized
  • MDCG published 2023-2: List of standard fees (NB), 23 January 2023 in Uncategorized
  • January 6, 2023: Press release of European Commission: Public health: more time to certify medical devices to mitigate risks of shortages, 6 January 2023 in Uncategorized
  • MDCG published guidance on the PSUR under the MDR, 16 December 2022 in Uncategorized
  • MDCG published guidance concerning a substantial modification of a performance study under the IVDR, 14 December 2022 in Uncategorized
  • MDCG published guidance regarding documents to be provided when an IVDR performance study is to be conducted, 12 December 2022 in Uncategorized
  • «
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 12
  • »

Stay informed

Please check your inbox or spam box to confirm

Copyright 2026 CEpartner4U | Esdoornlaan 13 | 3951 DB Maarn | The Netherlands | +31.6.516.536.26 | office@cepartner4u.com
  • enEnglish